GlycoMimetics, Inc. GLYC announced today that it will present at four investor conferences during the month of March, including:
30th Annual ROTH Conference
March
11 – 14, 2018, The Ritz Carlton, Dana Point, CA
CFO Brian Hahn
will present on March 12 at 3:30 p.m. PT.
Cowen 38th Annual Health Care Conference
March
11 – 14, 2018, Copley Place Marriott, Boston, MA
CEO Rachel
King will present on March 14 at 9:20 a.m. ET.
BioCentury: 25th Annual Future Leaders in
the BioTech Industry
March 23, 2018, Millennium Broadway
Hotel & Conference Center, New York, NY
Mrs. King will
present in room 311 at 2:30 p.m. ET.
Needham & Company's 17th Annual
HealthCare Conference
March 27 – 28, 2018, Westin Grand
Central Hotel, New York, NY
Mrs. King will present on March 27
at 8:00 a.m. ET.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005331/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.